

1 **Multomics profiling of human plasma and CSF reveals ATN derived** 2 **networks and highlights causal links in Alzheimer's disease**

3

4 Liu Shi^{a†}, Jin Xu^{b†}, Rebecca Green^{c,d,e}, Asger Wretling^f, Jan Homann^g, Noel J. Buckley^a, Betty M.
5 Tijms^h, Stephanie J. B. Vosⁱ, Christina M. Lill^{g,i,k}, Mara ten Kate^h, Sebastiaan Engelborghs^{l,m}, Kristel
6 Sleegers^{n,o}, Giovanni B. Frisoni^{p,q}, Anders Wallin^r, Alberto Lleó^s, Julius Pop^{t,u}, Pablo Martinez-Lage^v,
7 Johannes Streffer^w, Frederik Barkhof^{x,y}, Henrik Zetterberg^{z,aa,bb,cc}, Pieter Jelle Visser^{h,i}, Simon
8 Lovestone^{a,dd}, Lars Bertram^{g,ee}, Alejo J. Nevado-Holgado^a, Petroula Proitsis^{cs}, Cristina Legido-
9 Quigley^{b,f*§}

10 ^a Department of Psychiatry, University of Oxford, UK

11 ^b Institute of Pharmaceutical Science, King's College London, London, UK

12 ^c Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK

13 ^d UK National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre, South
14 London and Maudsley Trust, London, UK

15 ^e MRC Unit for Lifelong Health & Ageing at UCL, University College London, London, UK

16 ^f Steno Diabetes Center Copenhagen, Gentofte, Denmark

17 ^g Lübeck Interdisciplinary Platform for Genome Analytics, University of Lübeck, Lübeck, Germany

18 ^h Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands

19 ⁱ Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience,
20 Alzheimer Centrum Limburg, Maastricht University, Maastricht, the Netherlands

21 ^j Institute of Epidemiology and Social Medicine, University of Muenster, Muenster, Germany

22 ^k Ageing Epidemiology Research Unit (AGE), School of Public Health, Imperial College London,
23 London, UK

24 ^l Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of
25 Antwerp, Antwerp, Belgium

26 ^m Department of Neurology, UZ Brussel and Center for Neurosciences (C4N), Vrije Universiteit Brussel,
27 Brussels, Belgium

28 ⁿ Complex Genetics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium

29 ^o Institute Born-Bunge, Department of Biomedical Sciences, University of Antwerp, Antwerp,
30 Belgium

31 ^p University of Geneva, Geneva, Switzerland

32 ^q IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy

33 ^r Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg,
34 Gothenburg, Sweden

35 ^s Neurology Department, Hospital Sant Pau, Barcelona, Spain. Centro de Investigación en Red en
36 enfermedades neurodegenerativas (CIBERNED).

37 ^t University Hospital of Lausanne, Lausanne, Switzerland

38 ^u Geriatric Psychiatry, Department of Mental Health and Psychiatry, Geneva university Hospitals,
39 Geneva, Switzerland

40 ^v CITA-Alzheimer Foundation, San Sebastian, Spain

41 ^w AC Immune SA, Lausanne, Switzerland, formerly Janssen R&D, LLC. Beerse, Belgium at the time of
42 study conduct

43 ^x Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, The
44 Netherland

45 ^y Queen Square Institute of Neurology and Centre for Medical Image Computing, University College
46 London, UK

47 ^z Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden

48 ^{aa} Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology,
49 Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden

50 ^{bb} UK Dementia Research Institute at UCL, London, United Kingdom
51 ^{cc} Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom
52 ^{dd} Janssen Medical (UK), High Wycombe, UK
53 ^{ee} Department of Psychology, University of Oslo, Oslo, Norway

54
55
56

57 **+ Contributed equally**
58 **§ Senior authors with equal contribution**
59 ***correspondence:**
60 Cristina Legido-Quigley: cristina.legido_quigley@kcl.ac.uk
61

62 **Abstract (150 words limit)**

63 **INTRODUCTION:** This study employed an integrative system and causal inference approach to
64 explore molecular signatures in blood and CSF, the Amyloid/Tau/Neurodegeneration [AT(N)]
65 framework, MCI conversion to AD, and genetic risk for AD.

66 **METHODS:** Using the EMIF-AD MBD cohort, we measured 696 proteins in cerebrospinal fluid
67 (n=371), 4001 proteins in plasma (n=972), 611 metabolites in plasma (n=696) and genotyped data in
68 whole-blood (7,778,465 autosomal SNPs, n=936). We investigated associations: molecular modules
69 to AT(N), module hubs with AD Polygenic Risk scores and APOE4 genotypes, molecular hubs to MCI
70 conversion and probed for causality with AD using Mendelian Randomization (MR).

71 **RESULTS:** AT(N) framework associated key hubs were mostly proteins and few lipids. In MR analyses,
72 Proprotein Convertase Subtilisin/Kexin Type 7 showed weak causal associations with AD, and AD was
73 causally associated with Reticulocalbin 2 and sphingomyelins.

74 **DISCUSSION:** This study reveals multi-omics networks associated with AT(N) and MCI conversion and
75 highlights AD causal candidates.

76 **Key words:** Alzheimer's disease; multi-omics; AT(N) framework; polygenic risk score; Mendelian
77 randomization; multimodal biomarker

78

79 **1. Introduction**

80 Alzheimer's disease (AD) is characterised by the presence of β -amyloid (A β) containing plaques, and
81 neurofibrillary tangles composed of modified tau protein together with the progressive loss of
82 synapses and neurons [1]. The National Institute on Aging and Alzheimer's Association (NIA-AA) have
83 proposed to classify AD based on biomarkers of amyloid pathology (A), tau pathology (T), and
84 neurodegeneration (N) (the ATN framework) [2]. Yet, despite their diagnostic utility, these three
85 markers reflect only a portion of the complex pathophysiology of AD. In prodromal stages, the
86 interplay between AT(N) changes, genetic factors and peripheral molecular changes may affect the
87 rate of disease progression.

88 Conducting unbiased and high-throughput omics-based research in biological fluids and human brain
89 tissues provides a data-driven approach to identify the many processes involved in AD pathogenesis
90 and to prioritize links to relevant clinical and neuropathological traits. For example, an increasing
91 number of proteomics studies [3-5], including ours [6-8], have identified AD pathophysiological
92 pathways related to immune response and inflammation, oxidative stress, energy metabolism and
93 mitochondrial function. Metabolomics studies have also identified such pathways related to AD [9-
94 11]. A combination of omics, also called multi-omics or deep phenotyping studies, provides an
95 opportunity to explore the molecular interplay with both genotypic and phenotypic variability in AD,
96 bringing in new findings and uncovering novel pathways. Finally, causal inferences approaches allow
97 to scrutinize the causal relationship between molecular markers and AD, highlighting potential
98 interventional targets. Therefore, in this study, we conducted multi-omics analyses with four
99 modalities (cerebrospinal fluid [CSF] proteomics, plasma proteomics, plasma metabolomics and
100 whole blood genetics) from the EMIF-AD MBD study, followed by Mendelian Randomization (MR)
101 analyses (**Figure 1**).

102 We have four objectives: Firstly, we wanted to test if proteomic and metabolomic molecular
103 signatures were associated with AD endophenotypes including amyloid, CSF total tau (T-tau), CSF

104 phosphorylated tau (P-tau), white matter hyperintensity volume, CSF YKL-40, mini mental state
105 examination (MMSE) score, and mild cognitive impairment (MCI) conversion. Secondly, we wanted
106 to investigate the associations between molecular signatures and molecular hubs (main molecules
107 driving associations) with APOE4 genotypes and AD polygenic risk scores (PRS). Thirdly, we wanted
108 to query our findings in prodromal AD by extracting and integrating hub molecules in MCI individuals
109 that converted to AD by computing a network for MCI converters versus non-converters. Finally, MR
110 analyses interrogated the causal relationship between hub molecules and AD.

111

112 **2. Methods**

113 **2.1. Participants: EMIF-AD Multimodal Biomarker Discovery (MBD) study**

114 The EMIF-AD MBD study is part of the European Medical Information Framework for Alzheimer's
115 disease (EMIF; <http://www.emif.eu/emif-ad-2/>); a public-private partnership funded through the
116 Innovative Medicines Initiative (IMI). The design of the EMIF-AD MBD study has been described
117 previously [12]. Briefly, 1221 samples from three groups of people (cognitively normal controls [CTL],
118 MCI and AD) were chosen from pre-existing cohorts with the goal of including samples from people
119 with pathology as well as those without. All participating centres have agreed to share data as part
120 of the EMIF-AD MBD study.

121 General clinical and demographic information were available for all subjects (including *APOE* ϵ 4
122 genotype data). Furthermore, each participant had a measure of brain amyloid load, using either CSF
123 A β or amyloid positron emission tomography (PET) imaging. CSF T-tau and P-tau analysis data were
124 available for over 90% of the subjects. We used CSF (or where not available, PET) amyloid as "A", CSF
125 P-tau 181 as "T" and CSF T-tau as "N" to define the AT(N) framework. The classification of the status
126 (abnormal/normal) of amyloid, P-tau and T-tau has been described previously [12]. We
127 dichotomized these biomarkers as normal or abnormal and categorized them into four groups: no

128 pathology (A-T-N-, referring as “A-TN-”), amyloid positive but both T and N negative (A+T-N-,
129 referring as “A+TN-”), amyloid positive and T/N positive (including A+T-N+, A+T+N- and A+T+N+,
130 referring as “A+TN+”) and Suspected Non-Alzheimer Pathology (SNAP, including A-T-N+, A-T+N- and
131 A-T+N+). In addition, the following AD-related endophenotypes were also measured for the majority
132 of the subjects: (i) CSF YKL-40; (ii) MRI measures of white matter hyperintensities; (iii) clinical
133 assessments including baseline diagnosis, baseline MMSE score and MCI conversion [12].

134 **2.2. Omics analyses**

135 We performed multi-omics analyses for these subjects including CSF proteomics, plasma proteomics
136 and metabolomics as well as genome-wide SNP genotyping analyses (**Figure 1**).

137 *CSF proteomics*

138 We used tandem mass tag (TMT) technique to measure proteins in CSF. More details can be found in
139 [13]. We imputed proteins using K-nearest neighbour (K=10) and removed any missing > 70%,
140 leading to a total of 696 proteins in 371 samples for further analysis.

141 *Plasma proteomics*

142 We used the SOMAscan assay platform (SomaLogic Inc.) to measure proteins in plasma. SOMAscan
143 is an aptamer-based assay allowing for the simultaneous measurement and quantification of large
144 number of proteins. Here we measured 4001 proteins in 972 individuals. The details have been
145 described previously [14].

146 *Plasma metabolomics*

147 We measured plasma metabolites using Metabolon platform (Metabolon Inc.). Metabolites with
148 more than 70% missing were excluded and we imputed the missing metabolites using K-nearest
149 neighbour (K=10), resulting in 611 metabolites in 696 subjects for further analysis. More details can
150 be found in [11].

151 *Single nucleotide polymorphism (SNP) genotyping*

152 A detailed account of the genotyping procedures and subsequent bioinformatic workflows can be
153 found in [15]. Briefly, a total of 936 DNA samples were sent for genome-wide SNP genotyping using
154 the Infinium Global Screening Array (GSA) with Shared Custom Content (Illumina Inc.). After quality
155 control (QC) and imputation, a total of 7,778,465 autosomal SNPs with minor allele frequency (MAF)
156 ≥ 0.01 were retained in 898 individuals of European ancestry for downstream analyses and genetic
157 principal components (PCs) were computed [15].

158 **2.3. Statistical analysis**

159 All statistical analyses were completed using R (version 4.1.2). To compare baseline cohort
160 characteristics across three different diagnostic groups (CTL, MCI and AD), we used one-way analysis
161 of variance (ANOVA) and chi-square tests to compare continuous and binary variables, respectively.

162 *Weighted Gene Correlation Network Analysis (WGCNA)*

163 We used the R package WGCNA [16] to construct a weighted and unsigned co-expression network
164 for each individual omics layer. This clustering method is based on calculating correlations between
165 paired variables. The resulting modules or groups of co-expressed analytes were used to calculate
166 module eigenprotein/eigenmetabolite metrics. The eigenprotein/eigenmetabolite-based
167 connectivity (kME) value was used to represent the strength of an analyte's correlation with the
168 module. Analytes with high intramodular kME in the top 90th percentile within a module were
169 considered as hub proteins/metabolites.

170 The correlations between eigenprotein/eigenmetabolite and AD endophenotypes were calculated
171 using Spearman's correlation, the p values were corrected with false discovery rate (FDR) and
172 corrected p values are presented in a heat map. Furthermore, we used one way ANOVA test to
173 assess pairwise difference of eigenprotein/eigenmetabolite among different AT(N) framework.

174 *Pathway enrichment analysis*

175 Protein pathway enrichment analysis was performed using WebGestalt software
176 (<http://www.webgestalt.org/>). Briefly, proteins within a module were assembled into a “protein list”
177 and all proteins measured were used as “background”. This enrichment analysis was performed on
178 the KEGG database. Metabolite enrichment analysis was performed using the hypergeometric test.
179 The original 60 sub-pathways pre-defined by Metabolon based on the KEGG database were
180 employed as reference [17]. We further performed cell type enrichment analysis for CSF proteins
181 using BEST tool (<http://best.psych.ac.cn/#>).

182 *AD polygenic risk score (PRS) calculation*

183 The genome-wide association study summary statistics from Kunkle et al. [18] (N=63,926; 21,982 AD
184 clinically ascertained cases, 41,944 controls) were used as the reference data. PRS were constructed
185 using PRSice-2 [19], with and without SNPs in the *APOE* region (chr 19, GRCh37 coordinates
186 44912079 to 45912079) [20]. AD PRS were computed using two p-value thresholds (P_T), previously
187 recommended for PRS including and excluding the *APOE* region: 5×10^{-8} (*APOE* region included) and
188 0.1 (*APOE* region excluded) [21]. SNPs in linkage disequilibrium ($r^2 > 0.001$ within a 250kb window)
189 were clumped, retaining the SNP with the lowest p-value.

190 *Association of AD PRS and AT(N) with modules and hubs*

191 We used linear regression analyses to investigate the association of AD PRS (as predictor) with
192 eigenprotein/eigenmetabolite of AT(N) framework-related modules and hub proteins/metabolites
193 (with kME varying from top 90th percentile to top 98th percentile) in these modules, adjusting for
194 sex, age, and genetic PC1 to PC5 [22] (to control for population stratification). We used logistic
195 regression analyses to explore the association of AT(N) markers (as binary outcome) with hubs,
196 adjusting for sex, age and *APOE* $\epsilon 4$ genotype.

197 *Partial correlation network*

198 We used age, sex, *APOE* genotype, AD PRS ($P_T = 0.1$, *APOE* region excluded) and all hub
199 proteins/metabolites (with kME in the top 90th percentile) as input features for the graphical LASSO
200 algorithm and extended Bayesian information criterion to determine the model complexity for MCI
201 conversion using the R package ‘huge’ [23]. Data were auto-scaled prior to model-fitting. Partial
202 correlation network of selected metabolites, proteins and genetic variables was computed and
203 visualized with R package ‘qgraph’.

204 *Mendelian randomization*

205 We finally investigated whether any of the A/T/N hubs correlating with MCI conversion status were
206 causally linked to AD, by performing bi-directional two-sample Mendelian Randomization (MR)
207 analyses implemented in the “TwoSampleMR” R package [24] and the MendelianRandomization
208 package [25]. A number of sensitivity analyses for both single cis instrument MR and multiple (cis)
209 instruments MR (**Supplementary methods**) were applied to determine the robustness of the MR
210 findings.

211

212 **3. Results**

213 **3.1. Subject demographics**

214 **Table 1** shows the demographic information of subjects for each individual omics analysis. Despite
215 the difference in sample size for each omics layer analysis, no significant difference was observed in
216 the distribution of sex across different diagnostic groups. However, the CTL group was younger and
217 had a lower proportion of *APOE* $\epsilon 4$ carriers compared with the MCI and AD groups. Furthermore, the
218 CTL participants had longer education and higher MMSE score. In terms of AD pathology markers,
219 the ratio of abnormality of amyloid, P-tau and T-tau in AD and MCI individuals was, as expected,
220 significantly higher than in controls.

221

222 3.2 Co-expression network analysis of individual omics modalities reveals modules linked to AD 223 endophenotypes

224 We first performed a clustering analysis of the CSF proteome using WGCNA. We found four modules
225 (M) of co-expressed proteins. We ranked modules based on size from largest (M1 turquoise; n= 526
226 proteins) to smallest (M4 yellow; n=51 proteins) (**Figure 2A**, Table S1). We further investigated the
227 biological significance of proteins in each module and found that three modules (M1 turquoise, M2
228 blue and M4 yellow modules) were enriched with various pathways after FDR correction (**Figure 2B**).
229 When checking cell type enrichment, we found that all four modules were enriched with endothelial
230 cells. Furthermore, M1 turquoise module was enriched with oligodendrocytes, neurons and
231 astrocytes. M2 blue and M4 yellow modules were enriched with microglia (**Figure 2A**).

232 We then assessed the module correlations to AD endophenotypes. We used amyloid- β as "A", CSF P-
233 tau levels as a biomarker of tau ("T"), CSF T-tau as biomarkers of neurodegeneration ("N"), white
234 matter hyperintensity (WMH) volume as a biomarker for vascular disease burden ("V"), CSF YKL-40
235 as a biomarker of inflammation ("I") and MMSE score as "C" (**Figure 2A**). Overall, two (M1 and M4)
236 and three (M1, M2 and M3) modules were significantly associated with "T" and "N", respectively
237 after FDR correction. Furthermore, three (M1, M2 and M4) modules were associated with "I". None
238 of the modules were correlated with "A", "V", "C" or MCI conversion.

239 We used the same approach to analyse plasma proteomics and metabolomics data. We obtained
240 nine modules from plasma proteins (**Figure 2C**, previously published [26]). Four modules (M2, M3,
241 M4 and M8) had positive correlations with "A", "T" and "N". One (M3) and four (M1, M3, M8 and
242 M9) modules were associated with "V" and "I", respectively. In comparison, most plasma modules
243 were associated with "C" and MCI conversion. Furthermore, such associations were in concordance
244 with AT(N) markers correlations. For example, M2, M3, M4 and M8 modules were positively
245 associated with "A", "T" and "N" but were negatively correlated with MMSE score. Furthermore,
246 they were increased in MCI converters (n=103) compared with MCI non-converters (n=223) (**Figure**

247 **2C)**. We further investigated the biological significance of proteins in four AT(N) markers-related
248 modules (M2, M3, M4 and M8) and found that three of them were enriched with various pathways,
249 such as cytokine-cytokine receptor interaction and metabolic pathways (**Figure 2D**).

250 For plasma metabolomics, we obtained seven modules (**Figure 2E**), among which M4 module was
251 negatively associated with “A”, “T” and “N” and M3 module was positively associated with “N”.
252 Furthermore, one (M1) and two (M1 and M4) modules were associated with “V” and “I”,
253 respectively. Two (M3 and M4) and four (M1, M5, M6 and M7) modules were associated with “C”
254 and MCI conversion respectively. Furthermore, such associations were in concordance with AT(N)
255 markers correlations. We further investigated the biological significance of metabolites in AT(N)
256 markers-related modules (M3 and M4) and found that they were enriched in lipid pathways (**Figure**
257 **2F**).

258

259 **3.3 Correlation of individual omics modules with the AT(N) framework**

260 We dichotomized AT(N) biomarkers as normal or abnormal and categorized individuals into one of
261 four groups: A-T-N- (no pathology), A+TN- (amyloid pathology), A+TN+ (Alzheimer pathology) and A-
262 TN+ (SNAP). We then assessed the expression of each module eigenprotein/eigenmetabolite across
263 different ATN groups. For CSF protein modules, we found that three modules (M1 turquoise, M2
264 blue and M4 yellow) showed a significant difference across ATN profiles from one-way ANOVA test
265 (**Figure 3A-C**). Four plasma protein modules (M2 blue, M3 brown, M4 yellow and M8 pink, **Figure**
266 **3D-G**, adapted from [26]) and three plasma metabolites modules (M4 yellow, M5 green and M3
267 brown, **Figure 3H-J**) showed a significant difference across ATN profiles.

268

269 **3.4 Association between AT(N) framework-related modules and AD PRS**

270 We firstly selected AT(N) framework-related modules from each individual omics for further analysis.
271 As a result, we selected three CSF protein modules (M1 turquoise, M2 blue and M4 yellow), four
272 plasma protein modules (M2 blue, M3 brown, M4 yellow and M8 pink) and three plasma metabolite
273 modules (M3 brown, M4 yellow and M5 green). We then analysed the correlations between these
274 ten modules as well as between these modules and AD PRS. When analysing associations between
275 modules, we found that the metabolite M5 green module was negatively correlated with three
276 plasma protein modules (M2 blue, M3 brown and M8 pink). Additionally, a negative correlation was
277 observed between metabolite M3 brown module and plasma protein M8 pink module. In contrast, a
278 positive correlation was observed between metabolite M4 yellow module and plasma protein M4
279 yellow module as well as between metabolite M3 brown module and CSF protein M4 yellow module.
280 In addition, CSF protein M4 yellow module was positively associated with plasma protein M3 brown
281 module (**Figure 3K, Table S1-S3**).

282 When analysing the associations between these modules and AD PRS, we found that only plasma
283 protein modules were significantly associated with AD PRS. In detail, two plasma protein modules
284 (M2 blue and M4 yellow) were positively associated with PRS (*APOE* region included and excluded)
285 at $P_T=0.1$. Additionally, M2 blue module was significantly associated with PRS at 5×10^{-8} threshold
286 with *APOE* gene region included (**Figure 3K, Table S4**).

287

288 **3.5 Association of hub proteins/metabolites with AT(N) markers and AD PRS**

289 We selected hub proteins/metabolites within AT(N) framework-related modules and analysed the
290 association between these hub proteins/metabolites (with kME varying from top 90th percentile to
291 top 98th percentile, **Table S5**), as well as the association of these hub proteins/metabolite with AT(N)
292 markers and AD PRS. When checking the associations between hub metabolites and proteins, we
293 found that there was a strong correlation between metabolites and plasma proteins. In detail, five
294 metabolites (four phosphatidylethanolamines (PEs) and one LysoPE) correlated with most hub

295 proteins after controlling for multiple testing. Two metabolites (sphingomyelins [SM] d40:2 and
296 d41:2) in M3 brown module were correlated with proteins in plasma M8 pink module and CSF M4
297 yellow module. In contrast, relatively weak correlations were observed between CSF and plasma
298 proteins. (**Figure 4A, Table S6**).

299 We also investigated the association of these proteins/metabolites with AD PRS (*APOE* region
300 included and excluded (**Table S7**)). For plasma hub proteins, all 23 proteins in M2 blue module were
301 positively associated with AD PRS both at $P_T=5 \times 10^{-8}$ (*APOE* region included) and $P_T=0.1$ (*APOE* region
302 included and excluded). Similar trend was also observed for most proteins in M4 yellow module,
303 with only six proteins being positively associated with AD PRS at $P_T=5 \times 10^{-8}$ (*APOE* region included),
304 whereas most proteins, except for three, were associated with the $P_T=0.1$ AD PRS (with *APOE* and
305 without *APOE*) (**Figure 4A**). For hub metabolites, three SMs in M3 brown module and three PEs in
306 M5 green module were associated with AD PRS ($P_T=5 \times 10^{-8}$) with and without *APOE* region
307 respectively. However, such associations did not pass FDR correction (**Figure 4A** in light red). No
308 associations were observed between CSF hub proteins and AD PRS.

309 When investigating the association of hub proteins and metabolites with AT(N) markers, we found
310 that most CSF and plasma hub proteins were positively associated with amyloid, P-tau and T-tau
311 after FDR correction. In contrast, hub metabolites were negatively associated with amyloid, P-tau
312 and T-tau only at nominal level except for sphinganine (**Figure 4A**) (**Table S8**).

313 **3.6 Hub molecules integration in MCI conversion**

314 Having demonstrated the association of hub proteins/metabolites with AT(N) markers and AD PRS,
315 we then sought to find a multimodal signal that might shed insights on MCI conversion. To do this
316 we first used LASSO algorithm and extended Bayesian information criterion to select features from
317 age, sex, AD PRS ($P_T = 0.1$, *APOE* region excluded), *APOE* $\epsilon 4$ genotype and all plasma hub
318 metabolites/proteins (with kME in the top 90th percentile, **Table S9**) to predict MCI conversion. As a
319 result, AD PRS, *APOE* $\epsilon 4$ genotype and several metabolites/proteins were selected from LASSO. Of

320 the metabolites/proteins, two SMs, two PEs and one protein (proprotein convertase subtilisin/kexin
321 type 7 [PCSK7]) from the blue module were negatively correlated with MCI conversion while the rest
322 four selected proteins were positively associated with MCI conversion including reticulocalbin 2
323 (RCN2) from the blue module, and three proteins from the brown module: ephrin receptor tyrosine
324 kinase A2 (EFNA2), Collagen alpha-1(XV) chain (COL15A1) and AP-1 complex subunit gamma-like 2
325 (AP-1) (**Figure 4B**). In addition, correlations were also observed between metabolites/proteins and
326 AD PRS and *APOE* ϵ 4 genotype (**Figure 4B**).

327 **3.7 Causal links of hub proteins/metabolites with AD**

328 We finally used a bidirectional two-sample Mendelian randomization to determine whether there
329 was evidence for a causal relationship of MCI conversion related hub proteins/metabolites with
330 Alzheimer's disease. Using Wald ratio estimate, we observed weak associations between PCSK7 and
331 AD as well as between COL15A1 and AD using data from Sun et al. [27]. In sensitivity analyses, the
332 causal relationship between PCSK7 and AD was replicated using summary data from an independent
333 protein GWA study by Suhre et al. [28] (**Table 2**). Further support for causal effects for the
334 association of PCSK7 with AD came from multiple-cis instrument MR ($p < 0.001$ for IVW, 95% CI = 0.8
335 to 0.9, $N_{SNPs} = 4$, **Figure S4**), although this was not the case for COL15A1 (**Table S10**). Multiple-cis
336 instrument MR robust methods (MR-Egger and Weighted-median MR) and sensitivity analyses
337 estimates for PCSK7 were consistent with Wald ratio estimates in direction and magnitude, and
338 showed no horizontal pleiotropy or evidence of heterogeneity, further supporting the validity of the
339 MR assumptions (**Table S10**). In reverse MR analysis, we identified a causal association between
340 Alzheimer's disease, RCN2 and SM (**Table 2, Figure S1-3**). Robust methods and sensitivity analyses
341 provided additional support for such causal effects (**Table S10**).

342

343 **4. Discussion (words:1161)**

344 Alzheimer's disease is characterized by non-linear and heterogeneous biological alterations. Multi-
345 level biological networks underlie AD pathophysiology, including but not limited to proteostasis
346 (amyloid- β and tau), synaptic homeostasis, inflammatory and immune responses, lipid and energy
347 metabolism, and oxidative stress [30]. Therefore, a systems-level approach is needed to fully capture
348 AD multifaceted pathophysiology. Here we used unbiased and high throughput multi-omics profiling
349 of AD. We applied correlation network analysis to identify modules linked to a variety of AD
350 endophenotypes including "A", "T", "N", "V", "I" and "C". We found that four modules obtained
351 from CSF proteins were associated with at least one pathology marker of "T" (P-tau), "N" (T-tau) and
352 "I" (YKL-40). Furthermore, the three "I" related modules (M1 turquoise, M2 blue and M4 yellow)
353 were enriched with either microglia or astrocytes, which are key cellular drivers and regulators of
354 neuroinflammation [31], further indicating the consistency between correlation network analysis
355 and cell type enrichment analysis. In addition, of the four modules, three were enriched with various
356 pathways which have been reported being associated with Alzheimer's such as Ras signalling
357 pathway [32], axon guidance [33], cell adhesion molecules (CAMs) [34], and lysosome pathway [35],
358 further demonstrating the relatedness of these proteins with AD.

359 From plasma metabolomics, we found that the M3 brown module was associated with "N" (T-tau)
360 and "C" (cognition) and enriched with sphingolipid and ceramide metabolism. These findings align
361 with literature report as the lipids within this module have been reported being associated with
362 cognitive progression [36] and hippocampal atrophy [37]. In addition, M4 yellow module was
363 associated with five AD pathology markers ("A", "T", "N", "I" and "C") and enriched with three
364 pathways including gamma-glutamyl amino acid, plasmalogen, and polyamine metabolism. The
365 findings are also consistent with previous reports showing that these pathways were associated with
366 AD pathogenesis [38] and inflammatory cascade [39].

367 Two modules (M2 blue and M4 yellow) from plasma proteomics were associated with AD PRS (both
368 with and without *APOE* gene) at 0.1 level. Of the two modules, M2 blue module was associated with

369 PRS at 5×10^{-8} thresholds only when PRS included SNPs in the *APOE* region, indicating that such
370 association may be driven by *APOE*. Hub proteins in M2 blue module were correlated with PRS at
371 5×10^{-8} thresholds only with SNPs in the *APOE* region included, further indicating that associations
372 may be driven by *APOE*. For plasma metabolomics, three sphingomyelins (SMs) from M3 brown
373 module were associated PRS ($P_T = 5 \times 10^{-8}$) nominally only when the *APOE* region was included, also
374 indicating *APOE* gene dependence. This is in line with literature findings that nominal association
375 between SMs and PRS was reported [40].

376 We identified several closely correlated networks for metabolites, proteins, genetic factors, and MCI
377 conversion. Interestingly *APOE* and MCI conversion status were correlated to PCSK7 and
378 sphingomyelins SMs have been previously associated with cognitive progression in AD [41-43].
379 Furthermore, the integration of AD PRS showed that phosphatidylethanolamines [44, 45] and EFNA2
380 [46] were associated to both (MCI converter and AD PRS), with potential as early targets.

381 We finally investigated the causal relationship between A/T/N hubs associated with MCI conversion
382 status and AD. Our MR analyses highlighted a potential weak causal relationship between PCSK7 and
383 AD which was robust in both single and multiple cis instruments MR analyses and was replicated
384 using an independent pQTL dataset. We also found a causal relationship in the opposite direction,
385 whereby AD status is potentially causally linked to RCN2 that has been proposed as a therapeutic
386 target for atherosclerosis [47]. Finally, although we didn't have GWA summary data for the SM and
387 PE hubs examined in this study, our MR analyses showed that AD was causally linked to SM levels, as
388 previously shown when NMR data were used [48].

389 These findings are of great translational potential, particularly PCSK7 for which studies in Alzheimer's
390 disease are lacking. This convertase protein is very interesting as it is found in the BACE1 locus region
391 which encompasses several genes (PCSK7, RNF214, BACE1, CEP164) making it a plausible protein
392 activator of downstream amyloid deposition [49].

393 The causal associations from AD to RCN2 and sphingomyelins are also intriguing as both highlight a
394 possible vascular component caused by AD genetic liability, bringing new directionality between
395 vascular disease and dementia. These molecules and their potential causal links to AD suggest novel
396 avenues of research and intervention.

397 There are limitations for our study. First, the population in this study is of European ancestry and
398 mainly included participants who had high ratio of amyloid pathology and *APOE* ϵ 4 carriers.
399 Therefore, they are not necessarily representative of the broader community. Validation in
400 independent cohorts and particularly in other ethnic groups and community-based populations are
401 needed to see if the results are generalizable.

402 Despite this, our study is the largest study we are aware of to report multi-omics relating to AD
403 endophenotypes, particularly to the AT(N) framework. Our findings offer new insights into changes
404 in individual proteins/metabolites linked to AD endophenotypes, the AT(N) framework and AD PRS.
405 The nominated causal proteins/metabolites may be tractable targets for mechanistic studies of AD
406 pathology. Furthermore, they may represent promising drug targets in the early stages of AD.

407

408 **Conflict of Interest**

409 SL is named as an inventor on biomarker intellectual property protected by Proteome Sciences and
410 Kings College London unrelated to the current study and within the past five years has advised for
411 Optum labs, Merck, SomaLogic and been the recipient of funding from AstraZeneca and other
412 companies via the IMI funding scheme. HZ has served at scientific advisory boards and/or as a
413 consultant for Abbvie, Alector, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx,
414 Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, reMYND, Passage Bio,
415 Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in
416 symposia sponsored by Celectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of

417 Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator
418 Program (outside submitted work). AL has served at scientific advisory boards of Fujirebio Europe, Eli
419 Lilly, Novartis, Nutricia and Otsuka and is the inventor of a patent on synaptic markers in CSF (all
420 unrelated to this study). JP has served at scientific advisory boards of Fujirebio Europe, Eli Lilly and
421 Nestlé Institute of Health Sciences, all unrelated to this study. SE has received unrestricted research
422 grants from Janssen Pharmaceutica and ADx Neurosciences and has served at scientific advisory
423 boards of Biogen, Eisai, icometrix, Novartis, Nutricia / Danone, Pfizer, Roche, all unrelated to this
424 study. FB is a steering committee or iDMC member for Biogen, Merck, Roche, Eisai and Prothena.
425 Consultant for Roche, Biogen, Merck, IXICO, Jansen, Combinostics. Research agreements with Merck,
426 Biogen, GE Healthcare, Roche. Co-founder and shareholder of Queen Square Analytics LTD, all
427 unrelated to this study.

428 **Acknowledgements**

429 This research was conducted as part of the EMIF-AD MBD project which has received support from
430 the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement no 115372,
431 resources of which are composed of financial contribution from the European Union's Seventh
432 Framework Programme (FP7/2007-2013) and EFPIA companies' in-kind contribution. The DESCRIPA
433 study was funded by the European Commission within the 5th framework program (QLRT-2001-
434 2455). The EDAR study was funded by the European Commission within the 5th framework program
435 (contract # 37670). The Leuven cohort was funded by the Stichting voor Alzheimer Onderzoek (grant
436 numbers #11020, #13007 and #15005). RV is a senior clinical investigator of the Flemish Research
437 Foundation (FWO). The San Sebastian GAP study is partially funded by the Department of Health of
438 the Basque Government (allocation 17.0.1.08.12.0000.2.454.01.41142.001.H). We acknowledge the
439 contribution of the personnel of the Genomic Service Facility at the VIB-U Antwerp Center for
440 Molecular Neurology. The research at VIB-CMN is funded in part by the University of Antwerp
441 Research Fund. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council

442 (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical
443 Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-
444 2016862), and the UK Dementia Research Institute at UCL. FB is supported by the NIHR biomedical
445 research centre at UCLH. LS is funded by the Virtual Brain Cloud from European commission (grant
446 no. H2020-SC1-DTH-2018-1). R.G. was supported by the National Institute for Health Research (NIHR)
447 Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College
448 London. This paper represents independent research part-funded by the National Institute for
449 Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation
450 Trust and King's College London. The views expressed are those of the author(s) and not necessarily
451 those of the NHS, the NIHR or the Department of Health and Social Care. JX and CLQ thank Lundbeck
452 Fonden for the support (grant no. R344-2020-989).

453 **Ethics Statement**

454 Written informed consent was obtained from all participants before inclusion in the study. The
455 medical ethics committee at each site approved the study.

456 **Data Availability**

457 The datasets generated and analysed during the current study are available from the EMIF-AD
458 Catalogue via submitted research proposals which have to be approved by the data-owners from
459 each parent cohort.

460 **References**

- 461 1. Knopman, D.S., et al., *Alzheimer disease*. Nat Rev Dis Primers, 2021. **7**(1): p. 33.
- 462 2. Jack, C.R., Jr., et al., *NIA-AA Research Framework: Toward a biological definition of*
463 *Alzheimer's disease*. *Alzheimers Dement*, 2018. **14**(4): p. 535-562.
- 464 3. Johnson, E.C.B., et al., *Large-scale proteomic analysis of Alzheimer's disease brain and*
465 *cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and*
466 *astrocyte activation*. *Nat Med*, 2020. **26**(5): p. 769-780.
- 467 4. Higginbotham, L., et al., *Integrated proteomics reveals brain-based cerebrospinal fluid*
468 *biomarkers in asymptomatic and symptomatic Alzheimer's disease*. *Sci Adv*, 2020. **6**(43).

- 469 5. Butterfield, D.A. and D. Boyd-Kimball, *Oxidative Stress, Amyloid- β Peptide, and Altered Key*
470 *Molecular Pathways in the Pathogenesis and Progression of Alzheimer's Disease.* J
471 *Alzheimers Dis*, 2018. **62**(3): p. 1345-1367.
- 472 6. Ashton, N.J., et al., *Blood protein predictors of brain amyloid for enrichment in clinical trials?*
473 *Alzheimers Dement (Amst)*, 2015. **1**(1): p. 48-60.
- 474 7. Hye, A., et al., *Plasma proteins predict conversion to dementia from prodromal disease.*
475 *Alzheimers Dement*, 2014. **10**(6): p. 799-807.e2.
- 476 8. Shi, L., et al., *Discovery and validation of plasma proteomic biomarkers relating to brain*
477 *amyloid burden by SOMAscan assay.* *Alzheimers Dement*, 2019. **15**(11): p. 1478-1488.
- 478 9. Wilkins, J.M. and E. Trushina, *Application of Metabolomics in Alzheimer's Disease.* *Front*
479 *Neurol*, 2017. **8**: p. 719.
- 480 10. Tönnies, E. and E. Trushina, *Oxidative Stress, Synaptic Dysfunction, and Alzheimer's Disease.* J
481 *Alzheimers Dis*, 2017. **57**(4): p. 1105-1121.
- 482 11. Kim, M., et al., *Primary fatty amides in plasma associated with brain amyloid burden,*
483 *hippocampal volume, and memory in the European Medical Information Framework for*
484 *Alzheimer's Disease biomarker discovery cohort.* *Alzheimers Dement*, 2019. **15**(6): p. 817-827.
- 485 12. Bos, I., et al., *The EMIF-AD Multimodal Biomarker Discovery study: design, methods and*
486 *cohort characteristics.* *Alzheimers Res Ther*, 2018. **10**(1): p. 64.
- 487 13. Tijms, B.M., et al., *Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal*
488 *fluid proteomics.* *Brain*, 2020. **143**(12): p. 3776-3792.
- 489 14. Shi, L., et al., *Discovery and validation of plasma proteomic biomarkers relating to brain*
490 *amyloid burden by SOMAscan assay.* *Alzheimer's & Dementia*, 2019. **15**(11): p. 1478-1488.
- 491 15. Hong, S., et al., *Genome-wide association study of Alzheimer's disease CSF biomarkers in the*
492 *EMIF-AD Multimodal Biomarker Discovery dataset.* *Transl Psychiatry*, 2020. **10**(1): p. 403.
- 493 16. Langfelder, P. and S. Horvath, *WGCNA: an R package for weighted correlation network*
494 *analysis.* *BMC Bioinformatics*, 2008. **9**: p. 559.
- 495 17. Xu, J., et al., *Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD)*
496 *Endophenotypes in the European Medical Information Framework for AD Multimodal*
497 *Biomarker Discovery Cohort.* *Biomedicines*, 2021. **9**(11).
- 498 18. Kunkle, B.W., et al., *Genetic meta-analysis of diagnosed Alzheimer's disease identifies new*
499 *risk loci and implicates A β , tau, immunity and lipid processing.* *Nat Genet*, 2019. **51**(3): p.
500 414-430.
- 501 19. Euesden, J., C.M. Lewis, and P.F. O'Reilly, *PRSice: Polygenic Risk Score software.*
502 *Bioinformatics*, 2015. **31**(9): p. 1466-8.
- 503 20. Zettergren, A., et al., *Association between polygenic risk score of Alzheimer's disease and*
504 *plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging*
505 *Initiative.* *Alzheimers Res Ther*, 2021. **13**(1): p. 17.
- 506 21. Leonenko, G., et al., *Identifying individuals with high risk of Alzheimer's disease using*
507 *polygenic risk scores.* *Nat Commun*, 2021. **12**(1): p. 4506.
- 508 22. Hong, S., et al., *TMEM106B and CPOX are genetic determinants of cerebrospinal fluid*
509 *Alzheimer's disease biomarker levels.* *Alzheimers Dement*, 2021. **17**(10): p. 1628-1640.
- 510 23. Tofté, N., et al., *Metabolomic Assessment Reveals Alteration in Polyols and Branched Chain*
511 *Amino Acids Associated With Present and Future Renal Impairment in a Discovery Cohort of*
512 *637 Persons With Type 1 Diabetes.* *Front Endocrinol (Lausanne)*, 2019. **10**: p. 818.
- 513 24. Hemani, G., et al., *The MR-Base platform supports systematic causal inference across the*
514 *human phenome.* *Elife*, 2018. **7**.
- 515 25. Yavorska, O.O. and S. Burgess, *MendelianRandomization: an R package for performing*
516 *Mendelian randomization analyses using summarized data.* *Int J Epidemiol*, 2017. **46**(6): p.
517 1734-1739.
- 518 26. Shi, L., et al., *Replication study of plasma proteins relating to Alzheimer's pathology.*
519 *Alzheimers Dement*, 2021. **17**(9): p. 1452-1464.

- 520 27. Sun, B.B., et al., *Genomic atlas of the human plasma proteome*. Nature, 2018. **558**(7708): p.
521 73-79.
- 522 28. Suhre, K., et al., *Connecting genetic risk to disease end points through the human blood*
523 *plasma proteome*. Nat Commun, 2017. **8**: p. 14357.
- 524 29. Borges, M.C., et al., *Circulating Fatty Acids and Risk of Coronary Heart Disease and Stroke:*
525 *Individual Participant Data Meta-Analysis in Up to 16 126 Participants*. J Am Heart Assoc,
526 2020. **9**(5): p. e013131.
- 527 30. Hampel, H., et al., *Omics sciences for systems biology in Alzheimer's disease: State-of-the-art*
528 *of the evidence*. Ageing Res Rev, 2021. **69**: p. 101346.
- 529 31. Hampel, H., et al., *A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in*
530 *Alzheimer's Disease*. Front Immunol, 2020. **11**: p. 456.
- 531 32. Kirouac, L., et al., *Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein*
532 *and Amyloid Beta Facilitates Neurodegeneration in Alzheimer's Disease*. eNeuro, 2017. **4**(2).
- 533 33. Zhang, L., et al., *Roles and Mechanisms of Axon-Guidance Molecules in Alzheimer's Disease*.
534 Mol Neurobiol, 2021. **58**(7): p. 3290-3307.
- 535 34. Nagappan-Chettiar, S., E.M. Johnson-Venkatesh, and H. Umemori, *Activity-dependent*
536 *proteolytic cleavage of cell adhesion molecules regulates excitatory synaptic development*
537 *and function*. Neurosci Res, 2017. **116**: p. 60-69.
- 538 35. Zhang, Y., et al., *The role of ubiquitin proteasomal system and autophagy-lysosome pathway*
539 *in Alzheimer's disease*. Rev Neurosci, 2017. **28**(8): p. 861-868.
- 540 36. Kalinichenko, L.S., et al., *Sphingolipid control of cognitive functions in health and disease*.
541 Prog Lipid Res, 2022. **86**: p. 101162.
- 542 37. Kim, M., et al., *Association between Plasma Ceramides and Phosphatidylcholines and*
543 *Hippocampal Brain Volume in Late Onset Alzheimer's Disease*. J Alzheimers Dis, 2017. **60**(3):
544 p. 809-817.
- 545 38. Mahajan, U.V., et al., *Dysregulation of multiple metabolic networks related to brain*
546 *transmethylation and polyamine pathways in Alzheimer disease: A targeted metabolomic*
547 *and transcriptomic study*. PLoS Med, 2020. **17**(1): p. e1003012.
- 548 39. Bozelli, J.C., Jr., S. Azher, and R.M. Epanand, *Plasmalogens and Chronic Inflammatory Diseases*.
549 Front Physiol, 2021. **12**: p. 730829.
- 550 40. Liu, Y., et al., *Plasma lipidome is dysregulated in Alzheimer's disease and is associated with*
551 *disease risk genes*. Transl Psychiatry, 2021. **11**(1): p. 344.
- 552 41. Mielke, M.M., et al., *Plasma sphingomyelins are associated with cognitive progression in*
553 *Alzheimer's disease*. J Alzheimers Dis, 2011. **27**(2): p. 259-69.
- 554 42. He, X., et al., *Deregulation of sphingolipid metabolism in Alzheimer's disease*. Neurobiol
555 Aging, 2010. **31**(3): p. 398-408.
- 556 43. Morrow, A.R., et al., *CSF sphingomyelin metabolites in Alzheimer's disease,*
557 *neurodegeneration, and neuroinflammation*. Alzheimer's & Dementia, 2021. **17**: p. e052290.
- 558 44. Llano, D.A. and V. Devanarayan, *Serum Phosphatidylethanolamine and*
559 *Lysophosphatidylethanolamine Levels Differentiate Alzheimer's Disease from Controls and*
560 *Predict Progression from Mild Cognitive Impairment*. J Alzheimers Dis, 2021. **80**(1): p. 311-
561 319.
- 562 45. Calzada, E., O. Onguka, and S.M. Claypool, *Phosphatidylethanolamine Metabolism in Health*
563 *and Disease*. Int Rev Cell Mol Biol, 2016. **321**: p. 29-88.
- 564 46. Ma, X., et al., *Metabolic Reprogramming of Microglia Enhances Proinflammatory Cytokine*
565 *Release through EphA2/p38 MAPK Pathway in Alzheimer's Disease*. J Alzheimers Dis, 2022.
- 566 47. Li, J., et al., *Reticulocalbin 2 as a Potential Biomarker and Therapeutic Target for*
567 *Atherosclerosis*. Cells, 2022. **11**(7).
- 568 48. Compton, H., et al., *Effects of genetic liability to Alzheimer's disease on circulating*
569 *metabolites across the life course*. medRxiv, 2022: p. 2022.03.24.22272867.

570 49. Damotte, V., et al., *Plasma amyloid β levels are driven by genetic variants near APOE, BACE1,*
571 *APP, PSEN2: A genome-wide association study in over 12,000 non-demented participants.*
572 *Alzheimers Dement*, 2021. **17**(10): p. 1663-1674.

573

574

575 **Table 1. Demographics of participants included in multi-omics analysis by diagnosis.** One-way
 576 analysis of variance (ANOVA) and chi-square tests were used to compare continuous and binary
 577 variables, respectively. Percentage of cases is shown in brackets for male sex, *APOE* ϵ 4 carriers and
 578 the abnormality of amyloid, P-tau and T-tau.

Characteristics	Sample size	CTL	MCI	AD	P value
CSF proteomics					
n	371	123	154	94	NA
Age mean (SD), y	371	64.4 (7.8)	69.0 (7.4)	68.1 (8.1)	<0.001
Male sex N (%)	371	66 (54)	77 (50)	49 (52)	0.83
<i>APOE</i> ϵ 4+ N (%)	371	45 (37)	78 (51)	59 (63)	<0.001
MMSE (SD)	370	28.7 (1.3)	26.5 (2.7)	22.1 (3.8)	<0.001
Education mean (SD), y	371	12.4 (3.5)	10.8 (3.6)	10.1 (3.8)	<0.001
Amyloid + N (%)	371	41 (33)	77 (50)	81 (86)	<0.001
P-tau + N (%)	367	29 (24)	87 (58)	69 (73)	<0.001
T-tau + N (%)	365	28 (23)	82 (55)	74 (80)	<0.001
Plasma proteomics					
n	972	372	409	191	NA
Age mean (SD), y	972	64.6 (8.0)	69.9 (8.0)	70.5 (8.8)	<0.001
Male sex N (%)	972	209 (56)	216 (53)	103 (54)	0.64
<i>APOE</i> ϵ 4+ N (%)	972	139 (37)	195 (48)	116 (61)	<0.001
MMSE (SD)	967	28.8 (1.2)	26.2 (2.6)	21.4 (4.7)	<0.001
Education mean (SD), y	972	12.8 (3.7)	11.0 (3.7)	10.3 (3.9)	<0.001
Amyloid + N (%)	972	112 (30)	254 (62)	168 (88)	<0.001
P-tau + N (%)	876	53 (19)	215 (53)	128 (67)	<0.001
T-tau + N (%)	880	54 (19)	235 (58)	152 (80)	<0.001
Plasma metabolomics					
n	696	284	275	137	NA
Age mean (SD), y	696	65.0 (7.9)	70.0 (8.1)	70.1 (8.5)	<0.001
Male sex N (%)	696	155 (55)	141 (51)	81 (59)	0.60
<i>APOE</i> ϵ 4+ N (%)	696	111 (39)	153 (56)	84 (61)	<0.001
MMSE (SD)	691	28.8 (1.1)	25.7 (2.8)	21.5 (4.8)	<0.001
Education mean (SD), y	696	12.8 (3.8)	11.1 (3.4)	10.4 (3.7)	<0.001
Amyloid + N (%)	696	114 (40)	197 (72)	122 (89)	<0.001
P-tau + N (%)	641	44 (19)	161 (59)	93 (68)	<0.001
T-tau + N (%)	641	45 (19)	177 (65)	107 (79)	<0.001

579 CTL, cognitively normal controls; MCI, mild cognitive impairment; AD, Alzheimer's disease; CSF,
 580 cerebrospinal fluid; SD, standard deviation; MMSE, mini mental state examination; +, abnormality;
 581 P-tau, phosphorylated tau; T-tau, total tau.

582 **Table 2. Examination of the causal relationship between hub proteins/metabolites and**
 583 **Alzheimer's using bidirectional Mendelian randomization**

Protein	Estimate*					
	Forward (hub proteins/metabolites →Alzheimer's disease)			Backward (Alzheimer's disease→ hub proteins/metabolites)		
	No. of SNPs	Slope (95% CI)	P value	No. of SNPs	Slope (95% CI)	P value
PCSK7	1 [27]	0.88 (0.79 - 0.99)	0.029	20	0.06 (-0.14 - 0.02)	0.135
PCSK7	1 [28]	0.96 (0.93 - 0.99)	0.027	NA	NA	NA
RCN2	1 [27]	1.04 (0.87 - 1.24)	0.648	20	0.10 (0.03 - 0.17)	0.004
EFNA2	1 [27]	1.04 (0.81 - 1.34)	0.741	20	-0.02 (-0.09 - 0.06)	0.679
AP-1	1 [27]	0.84 (0.67 - 1.04)	0.114	20	-0.01 (-0.09 - 0.07)	0.804
COL15A1	1 [27]	1.15 (1.01 - 1.30)	0.032	20	0.02 (-0.05 - 0.09)	0.544
SM	58 [29]	1.28 (0.87 - 1.89)	0.212**	21	0.14 (0.03 - 0.24) ***	0.012

584 *The Wald ratio estimate and inverse variance weighting (IVW) estimate were used for MR analyses with a
 585 single and multiple SNPs, respectively.

586 ** Cochran's Q p<0.001

587 ***there was significant heterogeneity even after removing APOE (Cochran's Q p<0.05).

588

589 **Figure Legends**

590 **Figure 1. Flowchart of study design.** CTL, cognitively normal controls; MCI, mild cognitive
591 impairment; AD, Alzheimer's disease; A β , β -amyloid; CSF, cerebrospinal fluid; A, amyloid pathology;
592 T, tau pathology; N, neurodegeneration; PRS, polygenic risk score; MR, mendelian randomization.

593 **Figure 2. Individual omics modules correlating to AD endophenotypes.** (A) Weighted gene
594 correlation network analysis (WGCNA) of the CSF proteomics and cell type enrichment analysis of
595 modules; (B) Enriched KEGG pathways of three modules in CSF proteins; (C) WGCNA of plasma
596 proteomics; (D) Enriched KEGG pathways of three modules in plasma proteins; (E) WGCNA of plasma
597 metabolomics; (F) Enriched KEGG pathways of two modules in plasma metabolites. * and ** denote
598 significant correlations $p < 0.05$ and $p < 0.001$ after false discovery rate (FDR) correction respectively;
599 CSF, cerebrospinal fluid; "A", amyloid; "T", tau; "N", neurodegeneration; "V", vascular; "I",
600 inflammation; "C", cognition; +, abnormality; P-tau, phosphorylated tau; T-tau, total tau; WMH,
601 white matter hyperintensity; MMSE, mini mental state examination; MCI, mild cognitive impairment.

602 **Figure 3. Protein and metabolite modules correlate to AT(N) profile and AD PRS.** The relationship
603 of the AT(N) framework with (A-C) three CSF protein modules, (D-G) four plasma protein modules,
604 (H-J) three plasma metabolite modules, (K) Relation of AT(N) framework-related modules with AD
605 PRS (with and without *APOE* region) at two thresholds ($PT=5 \times 10^{-8}$ & 0.1); red and blue links denoted
606 positive and negative correlations, respectively. CSF, cerebrospinal fluid; SNAP, Suspected Non-
607 Alzheimer Pathology.

608 **Figure 4. (A) Relation of hub proteins/metabolites with AT(N) markers and PRS;** hub
609 proteins/metabolites from three CSF protein modules (M1 turquoise, M2 blue and M4 yellow), four
610 plasma protein modules (M2 blue, M3 brown, M4 yellow and M8 pink), and three plasma metabolite
611 modules (M4 yellow, M5 green and M3 brown); red, blue, light red and light blue squares denoted
612 positive association at FDR level ($pFDR < 0.05$), negative association at FDR level ($pFDR < 0.05$), positive
613 association at nominal level ($p < 0.05$, $pFDR > 0.05$), and negative association at nominal level ($p < 0.05$,
614 $pFDR > 0.05$), respectively. **(B) Partial correlation network selected for hub metabolites/proteins,**
615 **genetic factors, and MCI conversion.** PRS, polygenic risk score; MCI, mild cognitive impairment.

CTL
(N=492)

MCI
(N=527)

AD
(N=202)



CSF (N=371)

Proteomics
(N=696)



Plasma (N=972)

Proteomics
(N=4001)



Plasma (N=696)

Metabolomics
(N=611)



Whole blood
(N=936)

Genetics



Co-expression network analysis

[AT(N)] framework



Integration analysis

[AT(N)] framework; AD polygenic risk score














Partial correlation network

MCI conversion to AD (MCI $c=77$, MCI $s=77$)




Mendelian randomization analysis






K



A



B

